WO1991015584A1 - Trypanosoma cruzi recombinant antigens and synthetic peptides for utilization in the immunological diagnosis of chagas disease - Google Patents
Trypanosoma cruzi recombinant antigens and synthetic peptides for utilization in the immunological diagnosis of chagas disease Download PDFInfo
- Publication number
- WO1991015584A1 WO1991015584A1 PCT/BR1991/000003 BR9100003W WO9115584A1 WO 1991015584 A1 WO1991015584 A1 WO 1991015584A1 BR 9100003 W BR9100003 W BR 9100003W WO 9115584 A1 WO9115584 A1 WO 9115584A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alanine
- arginine
- glutamic acid
- leucine
- lysine
- Prior art date
Links
- 241000223109 Trypanosoma cruzi Species 0.000 title claims abstract description 23
- 239000000427 antigen Substances 0.000 title claims abstract description 18
- 108091007433 antigens Proteins 0.000 title claims abstract description 18
- 102000036639 antigens Human genes 0.000 title claims abstract description 18
- 206010001935 American trypanosomiasis Diseases 0.000 title claims abstract description 13
- 208000024699 Chagas disease Diseases 0.000 title claims abstract description 12
- 238000003745 diagnosis Methods 0.000 title claims abstract description 11
- 230000001900 immune effect Effects 0.000 title claims abstract description 10
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 10
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 5
- 238000000034 method Methods 0.000 claims abstract description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims abstract 30
- 235000004279 alanine Nutrition 0.000 claims abstract 30
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims abstract 24
- 235000013922 glutamic acid Nutrition 0.000 claims abstract 24
- 239000004220 glutamic acid Substances 0.000 claims abstract 24
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract 23
- 239000004475 Arginine Substances 0.000 claims abstract 20
- 235000009697 arginine Nutrition 0.000 claims abstract 20
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract 20
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims abstract 18
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract 16
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract 16
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract 16
- 239000004472 Lysine Substances 0.000 claims abstract 16
- 235000005772 leucine Nutrition 0.000 claims abstract 16
- 235000018977 lysine Nutrition 0.000 claims abstract 16
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims abstract 15
- 235000003704 aspartic acid Nutrition 0.000 claims abstract 15
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims abstract 15
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims abstract 13
- 235000004554 glutamine Nutrition 0.000 claims abstract 9
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract 9
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims abstract 8
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract 8
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims abstract 8
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims abstract 8
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims abstract 8
- 235000013930 proline Nutrition 0.000 claims abstract 8
- 235000014393 valine Nutrition 0.000 claims abstract 8
- 239000004474 valine Substances 0.000 claims abstract 8
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims abstract 6
- 235000006109 methionine Nutrition 0.000 claims abstract 6
- 229930182817 methionine Natural products 0.000 claims abstract 6
- 235000004400 serine Nutrition 0.000 claims abstract 6
- 108020004511 Recombinant DNA Proteins 0.000 claims abstract 5
- 150000001413 amino acids Chemical group 0.000 claims abstract 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims abstract 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims abstract 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims abstract 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims abstract 4
- 235000009582 asparagine Nutrition 0.000 claims abstract 4
- 229960001230 asparagine Drugs 0.000 claims abstract 4
- 235000008729 phenylalanine Nutrition 0.000 claims abstract 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims abstract 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims abstract 3
- 239000004473 Threonine Substances 0.000 claims abstract 3
- 241000894006 Bacteria Species 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 claims 1
- 229960004717 insulin aspart Drugs 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- -1 isoiencine Chemical compound 0.000 claims 1
- VOMXSOIBEJBQNF-UTTRGDHVSA-N novorapid Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 VOMXSOIBEJBQNF-UTTRGDHVSA-N 0.000 claims 1
- 238000002965 ELISA Methods 0.000 abstract description 3
- 238000001262 western blot Methods 0.000 abstract description 3
- 230000004520 agglutination Effects 0.000 abstract description 2
- 230000035931 haemagglutination Effects 0.000 abstract description 2
- 229960003767 alanine Drugs 0.000 abstract 16
- 229960002989 glutamic acid Drugs 0.000 abstract 12
- 229960003121 arginine Drugs 0.000 abstract 10
- 229960005261 aspartic acid Drugs 0.000 abstract 8
- 229960003136 leucine Drugs 0.000 abstract 8
- 229960003646 lysine Drugs 0.000 abstract 8
- 229960002743 glutamine Drugs 0.000 abstract 5
- 229960002429 proline Drugs 0.000 abstract 4
- 229960004295 valine Drugs 0.000 abstract 4
- 229960001153 serine Drugs 0.000 abstract 3
- 229960004452 methionine Drugs 0.000 abstract 2
- 229960005190 phenylalanine Drugs 0.000 abstract 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 1
- 235000014705 isoleucine Nutrition 0.000 abstract 1
- 229960000310 isoleucine Drugs 0.000 abstract 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract 1
- 238000003127 radioimmunoassay Methods 0.000 abstract 1
- 244000045947 parasite Species 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- This patent request refers to the use of Trypanosoma cruzi repetitive recombinant antigens, as well as the corresponding synthetic peptides, in the immunological detection of Chagas Disease and its ethiological agent, the parasite Trypanosoma cruzi.
- the immunological diagnosis of Chagas Disease is in general based on the use of crude or semi-purified parasite extracts for the detection of antibodies, in different tests such as hemagglutination, ELISA, rad i o i mmunoassay and Western blot analysis.
- hemagglutination ELISA
- rad i o i mmunoassay Western blot analysis.
- it is generally observed the cross-reactivity with patients bearing other diseases such as visceral and tegumentar leishmaniasis, toxoplasmosis, syphilis and schistosomiasis,
- the use of parasite extracts involves some rises for its preparation and is relatively expensive.
- T.cruzi DNA was cloned in E.coli using the expression vector lambda gt11, and the recombinant clones were screened with a pool of human chagasic sera. Twelve recombinant clones were purified to homogeneity and from these two were selected on the basis of the specificity of their reactivity with chagasic sera. Partial nucleotide sequence of these clones showed that one of them (Ag#1) encodes an antigen composed of at least 23 repetitions of a 14 aminoacids motif whereas the other (Ag#2) encodes an antigen containing at least 14 repetitions of a 68 am i noac i ds repetitive epitope.
- Ag#1 encodes an antigen composed of at least 23 repetitions of a 14 aminoacids motif
- Ag#2 encodes an antigen containing at least 14 repetitions of a 68 am i noac i ds repetitive epitope.
Abstract
This patent deals with the use of Trypanosoma cruzi antigens obtained using recombinant DNA techniques, or synthetic peptides derived from these antigens, and their use in the immunological diagnosis of Chagas Disease using either ELISA, or western blot, or dot-blot, or hemagglutination, or agglutination, or monoclonal antibodies, or radioimmunoassay. The antigens or synthetic peptides are characterized by displaying the following aminoacid sequences: Ag1: valine (or alanine), alanine, glutamic acid, alanine (orthreonine), glutamic acid, lysine, glutamine, lysine (or arginine), alanine, alanine, glutamic acid, alanine (or serine), threonine (or methionine or alanine) and lysine. Ag2: methionine, glutamic acid, glutamine, glutamic acid arginine, arginine, glutamine, leucine, leucine, glutamic acid, lysine, aspartic acid, proline, arginine, arginine, asparagine, alanine, lysine, glutamic acid, isoleucine alanine, alanine, leucine, glutamic acid, glutamic acid, serine, methionine, asparagine, alanine, arginine, alanine, glutamine, glutamic acid, leucine, alanine, arginine, glutamic acid, lysine, lysine, leucine, arginine, aspartic acid, arginine, alanine, phenylalanine, leucine, aspartic acid, glutamine, lysine, proline, glutamic acid, arginine, valine, proline, leucine, alanine, aspartic acid, valine, proline, leucine, aspartic acid, aspartic acid, aspartic acid, serine, aspartic acid, phenylalanine, valine and alanine.
Description
Trypanosoma cruzi RECOMBINANT ANTIGENS AND SYNTHETIC PEPTIDES FOR UTILIZATION IN THE IMMUNOLOGICAL DIAGNOSIS OF CHAGAS DISEASE.
BACKGROUND OF THE INVENTION
This patent request refers to the use of Trypanosoma cruzi repetitive recombinant antigens, as well as the corresponding synthetic peptides, in the immunological detection of Chagas Disease and its ethiological agent, the parasite Trypanosoma cruzi.
The immunological diagnosis of Chagas Disease is in general based on the use of crude or semi-purified parasite extracts for the detection of antibodies, in different tests such as hemagglutination, ELISA, rad i o i mmunoassay and Western blot analysis. However, it is generally observed the cross-reactivity with patients bearing other diseases such as visceral and tegumentar leishmaniasis, toxoplasmosis, syphilis and schistosomiasis,, Furthermore, the use of parasite extracts involves some rises for its preparation and is relatively expensive.
However, with the development of genetic engeneering techniques, it became possible to express heterologous genes in bacteria with low cost and high specificity. Then, the cloning and expression of Trypanosoma cruzi genes in E.coli was aimed for the obtention of parasite recombinant antigens that might be used for the diagnosis of Chagas Disease.,
DESCRIPTION OF THE INVENTION
T.cruzi DNA was cloned in E.coli using the expression
vector lambda gt11, and the recombinant clones were screened with a pool of human chagasic sera. Twelve recombinant clones were purified to homogeneity and from these two were selected on the basis of the specificity of their reactivity with chagasic sera. Partial nucleotide sequence of these clones showed that one of them (Ag#1) encodes an antigen composed of at least 23 repetitions of a 14 aminoacids motif whereas the other (Ag#2) encodes an antigen containing at least 14 repetitions of a 68 am i noac i ds repetitive epitope.
The recomb inant antigems Ag#1 and Ag#2, as well as a synthetic peptide corresponding to Ag#1, were tested in the immunological diagnosis of Chagas Disease, using the methods of ELISA, dot-blot, western blot and agglutination. The results obtained showed that the aforementioned antigens provide an adequate and specific diagnosis for Chagas Disease„
Claims
1) Trypanosoma cruzi antigen, obtained by recomb inant DNA technique and expressed in bacteria, comprising the following aminoacid sequence: Valine (or alanint), alanine, glutamic acid, alanine (or threonine), glutamic acid, lysine. glutamine, lysine (or arginine), aϊanine, alanine, glutamic acid, alanine (or serine), threonine (or methionine or alanine) and lysine.
2) Trypanosoma cruzi antigen, obtained by recombinant DNA thecnic, according to claim 1, wherein this ant igen include crude or semi-purified and recombinant ant igens, for utilization in the immunological diagnosis of Chagas Disease,,
3) Synthetic peptide comprising the same aminoacid sequence as claimed in claim 1„
4) Synthetic peptide, according to claim 3, for ut il izat ion in the immunological diagnosis of Chagas Disease,,
5) Trypanosoma cruzi antigen, obtained by recombinant DNA thecnic and expressed in bacteria, comprising the following aminoacid sequences Methionine, glutamic acid, glutamine, glutamic acid, arginine, arginine, glutamine, leucine, leucine, glutamic acid, lysine, aspartic acid, proline, arginine, arginine, asparagine, alanine, lysine, glutamic acid, isoiencine, alanine, alanine, leucine, glutamic acid , glutamic acid, serine, methionine, asparagine, alanine arginine alanine, g lu tamin e, glutamic acid, leucine, alanine, arginine glutamic acid, lysine, lysine, leucine, arginine, aspart ic acid,
arginine, alanine, phenylalanine, leucine, aspartic acid, glutamine, lysine, proline, glutamic acid, arginine, valine, proline, leucine, alanine, aspartic acid, valine, proline, leucine, aspartic acid, aspartic acid, aspartic acid, serine, aspartic acid, phenylalanine, valine and alanine,
6) Trypanosoma cruzi antigen, obtained by recombinant DNA thecnic, according to claim 5, wherein this antigen include crude or semi-purified and recombinant antigens, for utilization in the immunological diagnosis of Chagas Disease,
7) Synthetic peptide comprising the same aminoacid sequence as claimed in claim 5.
8) Synthetic peptide, according to claim 7, for utilization in the immunological diagnosis of Chagas Disease,
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR909001479A BR9001479A (en) | 1990-03-30 | 1990-03-30 | ANTIGENS OF TRYPANOSOMA CRUZI, AS WELL AS SYNTHETIC POLIPEPTIDEOS, FOR USE IN THE DIAGNOSIS OF CHAGAS DISEASE |
| BR9001479 | 1990-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1991015584A1 true WO1991015584A1 (en) | 1991-10-17 |
Family
ID=4049195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/BR1991/000003 WO1991015584A1 (en) | 1990-03-30 | 1991-04-01 | Trypanosoma cruzi recombinant antigens and synthetic peptides for utilization in the immunological diagnosis of chagas disease |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP0486627A1 (en) |
| BR (1) | BR9001479A (en) |
| WO (1) | WO1991015584A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992009895A1 (en) * | 1990-11-28 | 1992-06-11 | Fundação Oswaldo Cruz (Fiocruz) - Superintendência De Planejamento | Composition and its preparation process using antigen conjugated to enzymatic activity for immunological diagnosis and chagas' disease immunological diagnosis kits, for individual and epidemiological application, based on that composition |
| FR2692900A1 (en) * | 1992-06-25 | 1993-12-31 | Pasteur Institut | New Trypanosoma cruzi immunogen peptide(s) - and antibodies and nucleic acids, useful for vaccination or diagnosis |
| US5876734A (en) * | 1994-03-24 | 1999-03-02 | Kirchhoff; Louis V. | Polypeptides for diagnosing infection with Trypanosoma cruzi |
| US7749717B2 (en) | 2006-10-19 | 2010-07-06 | Abbott Laboratories | Methods for the detection and diagnosis of Trypanosoma cruzi infection |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0003529A1 (en) * | 1978-01-25 | 1979-08-22 | The Wellcome Foundation Limited | Antigens from Trypanosoma cruzi, purification thereof, and their use in vaccines |
| DE3012204A1 (en) * | 1979-03-29 | 1980-10-23 | Wellcome Found | ANTIGEN, PROCESS FOR ITS PRODUCTION AND ITS USE |
| EP0138101A1 (en) * | 1983-09-30 | 1985-04-24 | Rockefeller University | Genetically engineered organisms expressing surface proteins of T. Cruzi |
| EP0273555A2 (en) * | 1986-11-04 | 1988-07-06 | Codon | Antigenic material for a chagas' disease detection system |
-
1990
- 1990-03-30 BR BR909001479A patent/BR9001479A/en not_active Application Discontinuation
-
1991
- 1991-04-01 EP EP91906678A patent/EP0486627A1/en not_active Withdrawn
- 1991-04-01 WO PCT/BR1991/000003 patent/WO1991015584A1/en not_active Application Discontinuation
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0003529A1 (en) * | 1978-01-25 | 1979-08-22 | The Wellcome Foundation Limited | Antigens from Trypanosoma cruzi, purification thereof, and their use in vaccines |
| DE3012204A1 (en) * | 1979-03-29 | 1980-10-23 | Wellcome Found | ANTIGEN, PROCESS FOR ITS PRODUCTION AND ITS USE |
| EP0138101A1 (en) * | 1983-09-30 | 1985-04-24 | Rockefeller University | Genetically engineered organisms expressing surface proteins of T. Cruzi |
| EP0273555A2 (en) * | 1986-11-04 | 1988-07-06 | Codon | Antigenic material for a chagas' disease detection system |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992009895A1 (en) * | 1990-11-28 | 1992-06-11 | Fundação Oswaldo Cruz (Fiocruz) - Superintendência De Planejamento | Composition and its preparation process using antigen conjugated to enzymatic activity for immunological diagnosis and chagas' disease immunological diagnosis kits, for individual and epidemiological application, based on that composition |
| FR2692900A1 (en) * | 1992-06-25 | 1993-12-31 | Pasteur Institut | New Trypanosoma cruzi immunogen peptide(s) - and antibodies and nucleic acids, useful for vaccination or diagnosis |
| US5876734A (en) * | 1994-03-24 | 1999-03-02 | Kirchhoff; Louis V. | Polypeptides for diagnosing infection with Trypanosoma cruzi |
| US6228601B1 (en) | 1994-03-24 | 2001-05-08 | Louis V. Kirchhoff | Polypeptides for diagnosing infection with trypanosoma cruzi |
| US7749717B2 (en) | 2006-10-19 | 2010-07-06 | Abbott Laboratories | Methods for the detection and diagnosis of Trypanosoma cruzi infection |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0486627A1 (en) | 1992-05-27 |
| BR9001479A (en) | 1991-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2675009B2 (en) | Improved peptide composition and method for detecting antibodies to HIV | |
| EP0683234B2 (en) | Antibody against beta-amyloid or their derivative and use thereof | |
| US5955317A (en) | Antibodies to β-amyloids or their derivatives and use thereof | |
| US5756662A (en) | Compounds and methods for the detection of T. cruzi infection | |
| US20060039924A1 (en) | Isolated antibodies crossreactive with peptides used to detect rheumatoid arthritis | |
| JPH07260783A (en) | Catamer having antigen activity of foot and mouth disease virus | |
| AU7234387A (en) | Synthetic htlv-iii peptides, compositions and uses thereof | |
| PT1881064E (en) | Hcv-anti-core monoclonal antibody | |
| CA2391356A1 (en) | Peptides designed for the diagnosis and treatment of rheumatoid arthritis | |
| EP1155322B1 (en) | Compounds and methods for diagnosing trypanosoma cruzi infection | |
| Teisner et al. | Fetal antigen 2: an amniotic protein identified as the aminopropeptide of the α1 chain of human procollagen type I | |
| Fujii et al. | Localization of biologically uncommon D-beta-aspartate-containing alphaA-crystallin in human eye lens | |
| WO1997018475A1 (en) | Compounds and methods for the detection and prevention of t. cruzi infection | |
| WO1991015584A1 (en) | Trypanosoma cruzi recombinant antigens and synthetic peptides for utilization in the immunological diagnosis of chagas disease | |
| EP0386166A1 (en) | PROTAMINE-REACTIVE IgM ANTIBODIES. | |
| Lowey et al. | Neonatal and adult myosin heavy chains form homodimers during avian skeletal muscle development. | |
| RU2001127439A (en) | Peptides from the sequence of the T virus and monospecific antibodies that bind to the TT virus | |
| US20060211056A1 (en) | Leishmania antigens suitable for a diagnostic kit of Leishmania | |
| EP1038000A1 (en) | Compounds and methods for the detection and prevention of (t. cruzi) infection | |
| JP4568842B2 (en) | Method for producing partial peptide of Enolase protein of Plasmodium falciparum | |
| Clarke et al. | Structural features of antigenic determinants on variant surface glycoproteins from Trypanosoma brucei | |
| Richman et al. | Peptide mapping of conformational epitopes in a human malarial parasite heat shock protein. | |
| Nagy et al. | Immunogenicity of a unique region of the human thyrotropin receptor | |
| EP0470205A1 (en) | New human parvovirus peptides with disulfide bridge for immunization or diagnosis | |
| JPH03128393A (en) | Treatment and diagnosis for human lymphatic nutritive virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1991906678 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1991906678 Country of ref document: EP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1991906678 Country of ref document: EP |